Sugi Predict

Sugi Predict / Compounds / SCHEMBL5111598

SCHEMBL5111598

SCHEMBL5111598

OB(O)c1ccn(C2CCCCO2)n1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 1/20 0.40
▸ CYP4F2 P78329 2/20 0.33
▸ CYP4A11 Q02928 2/20 0.33
▸ RXRA P19793 1/20 0.33
▸ RXRB P28702 1/20 0.33
▸ RXRG P48443 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ABL1 P00519 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ IDH1 O75874 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28492130 0.78 CD274 (0.39) CD274CYP4F2CYP4A11MEN1KMT2A
SCHEMBL18483949 0.77 CD274 (0.43) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL14094871 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL31042946 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL14726436 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL25187231 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL25405744 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL19204932 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL20237134 0.76 CD274 (0.40) CD274CYP4F2CYP4A11RXRARXRB
SCHEMBL16072020 0.76 ALDH1A1 (0.41) CD274CYP4F2CYP4A11RXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073745-A1 INHIBITORS OF EGFR OR HER2 AND METHODS OF USE ARBELLA THERAPEUTICS, LLC (US) 2024-04-04 — — WO disclosed
EP-3774805-B1 HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER SERVIER LAB (FR) 2024-01-10 — — EP disclosed
CN-111936499-B Heterobicyclic inhibitors of MAT2A and methods for treating cancer 法国施维雅药厂 2023-09-19 — — CN disclosed
US-11524960-B2 Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer SERVIER PHARMACEUTICALS LLC (US) 2022-12-13 — — US disclosed
US-20210115045-A1 HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER SERVIER PHARMACEUTICALS LLC 2021-04-22 — — US disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 — — CN disclosed
CN-111936499-A Heterobicyclic inhibitors of MAT2A and methods for treating cancer 安吉奥斯医药品有限公司 2020-11-13 — — CN disclosed
US-9353107-B2 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-05-31 — — US disclosed
US-9353107-B2 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-05-31 — — US disclosed
US-9353107-B2 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2016-05-31 — — US disclosed
US-20150336949-A1 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors Um Pharmauji Sdn. Bhd. (MY) 2015-11-26 — — US disclosed
US-20150336949-A1 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors Um Pharmauji Sdn. Bhd. (MY) 2015-11-26 — — US disclosed
US-20150336949-A1 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors Um Pharmauji Sdn. Bhd. (MY) 2015-11-26 — — US disclosed
EP-2867233-A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS Aurigene Discovery Technologies Limited (IN) 2015-05-06 — — EP disclosed
WO-2014006554-A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-01-09 — — WO disclosed
WO-2014006554-A1 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2014-01-09 — — WO disclosed
US-20080234276-A1 Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors SENTINEL ONCOLOGY LIMITED (UK) 2008-09-25 — — US disclosed
EP-1846392-A2 HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS Sentinel Oncology Limited (GB) 2007-10-24 — — EP disclosed
WO-2006131835-A2 HETEROCYCLIC TRIAZINES AS HYPOXIC SELECTIVE PROTEIN KINASE INHIBITORS SENTINEL ONCOLOGY LIMITED (GB) 2006-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115045-A1 HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER MAT2A, MAT2B, MAT1A CD274 4873/4885CYP4F2 824/4885CYP4A11 2929/4885
US-20080234276-A1 Heterocyclic Triazines as Hypoxic Selective Protein Kinase Inhibitors HIF1AN, HIF1A, CDK2 CD274 2870/4885CYP4F2 3735/4885CYP4A11 3453/4885
US-11524960-B2 Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer MAT2A, MAT2B, MAT1A CD274 4873/4885CYP4F2 824/4885CYP4A11 2929/4885
US-20150336949-A1 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors MAP3K3, MAP3K1, MAP3K6 CD274 4018/4885CYP4F2 1224/4885CYP4A11 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.